Abstract
For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is intended to summarize the current knowledge on first-line treatment of CLL.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anemia / epidemiology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chromosome Aberrations
-
Chromosome Deletion
-
Chromosomes, Human, Pair 11
-
Chromosomes, Human, Pair 13
-
Chromosomes, Human, Pair 17
-
Humans
-
Immunotherapy / methods
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Neoplasm Staging
-
Prognosis
-
Quality of Life
-
Rituximab
-
Thrombocytopenia / epidemiology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Rituximab